EGFR and non-small cell lung carcinoma: The first large-scale genome sequencing studies on NSCLC were primarily based on resected early-stage tumors not treated with TKIs, thus they supported the predominant view of one single, usually “mutually exclusive”, oncogenic driver, like the mutated EGFR [3,8].